333 related articles for article (PubMed ID: 30021702)
1. Sodium-glucose cotransporter 2 inhibition normalizes glucose metabolism and suppresses oxidative stress in the kidneys of diabetic mice.
Tanaka S; Sugiura Y; Saito H; Sugahara M; Higashijima Y; Yamaguchi J; Inagi R; Suematsu M; Nangaku M; Tanaka T
Kidney Int; 2018 Nov; 94(5):912-925. PubMed ID: 30021702
[TBL] [Abstract][Full Text] [Related]
2. Effects of sodium-glucose cotransporter 2 selective inhibitor ipragliflozin on hyperglycaemia, oxidative stress, inflammation and liver injury in streptozotocin-induced type 1 diabetic rats.
Tahara A; Kurosaki E; Yokono M; Yamajuku D; Kihara R; Hayashizaki Y; Takasu T; Imamura M; Li Q; Tomiyama H; Kobayashi Y; Noda A; Sasamata M; Shibasaki M
J Pharm Pharmacol; 2014 Jul; 66(7):975-87. PubMed ID: 24533859
[TBL] [Abstract][Full Text] [Related]
3. Acute and Direct Effects of Sodium-Glucose Cotransporter 2 Inhibition on Glomerular Filtration Rate in Spontaneously Diabetic Torii Fatty Rats.
Takakura S; Takasu T
Biol Pharm Bull; 2019; 42(10):1707-1712. PubMed ID: 31582658
[TBL] [Abstract][Full Text] [Related]
4. Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db/db mice.
Terami N; Ogawa D; Tachibana H; Hatanaka T; Wada J; Nakatsuka A; Eguchi J; Horiguchi CS; Nishii N; Yamada H; Takei K; Makino H
PLoS One; 2014; 9(6):e100777. PubMed ID: 24960177
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive renoprotective effects of ipragliflozin on early diabetic nephropathy in mice.
Kamezaki M; Kusaba T; Komaki K; Fushimura Y; Watanabe N; Ikeda K; Kitani T; Yamashita N; Uehara M; Kirita Y; Shiotsu Y; Sakai R; Fukuda T; Yamazaki M; Fukui M; Matoba S; Tamagaki K
Sci Rep; 2018 Mar; 8(1):4029. PubMed ID: 29507299
[TBL] [Abstract][Full Text] [Related]
6. The SGLT2 inhibitor empagliflozin ameliorates early features of diabetic nephropathy in BTBR ob/ob type 2 diabetic mice with and without hypertension.
Gembardt F; Bartaun C; Jarzebska N; Mayoux E; Todorov VT; Hohenstein B; Hugo C
Am J Physiol Renal Physiol; 2014 Aug; 307(3):F317-25. PubMed ID: 24944269
[TBL] [Abstract][Full Text] [Related]
7. Antidiabetic effects of SGLT2-selective inhibitor ipragliflozin in streptozotocin-nicotinamide-induced mildly diabetic mice.
Tahara A; Kurosaki E; Yokono M; Yamajuku D; Kihara R; Hayashizaki Y; Takasu T; Imamura M; Qun L; Tomiyama H; Kobayashi Y; Noda A; Sasamata M; Shibasaki M
J Pharmacol Sci; 2012; 120(1):36-44. PubMed ID: 22971845
[TBL] [Abstract][Full Text] [Related]
8. Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice.
Tahara A; Kurosaki E; Yokono M; Yamajuku D; Kihara R; Hayashizaki Y; Takasu T; Imamura M; Li Q; Tomiyama H; Kobayashi Y; Noda A; Sasamata M; Shibasaki M
Eur J Pharmacol; 2013 Sep; 715(1-3):246-55. PubMed ID: 23707905
[TBL] [Abstract][Full Text] [Related]
9. Empagliflozin protects glomerular endothelial cell architecture in experimental diabetes through the VEGF-A/caveolin-1/PV-1 signaling pathway.
Locatelli M; Zoja C; Conti S; Cerullo D; Corna D; Rottoli D; Zanchi C; Tomasoni S; Remuzzi G; Benigni A
J Pathol; 2022 Apr; 256(4):468-479. PubMed ID: 35000230
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of Sodium Glucose Cotransporter 2 Attenuates the Dysregulation of Kelch-Like 3 and NaCl Cotransporter in Obese Diabetic Mice.
Ishizawa K; Wang Q; Li J; Xu N; Nemoto Y; Morimoto C; Fujii W; Tamura Y; Fujigaki Y; Tsukamoto K; Fujita T; Uchida S; Shibata S
J Am Soc Nephrol; 2019 May; 30(5):782-794. PubMed ID: 30914436
[TBL] [Abstract][Full Text] [Related]
11. Effects of the SGLT2 inhibitor ipragliflozin on various diabetic symptoms and progression of overt nephropathy in type 2 diabetic mice.
Tahara A; Takasu T
Naunyn Schmiedebergs Arch Pharmacol; 2018 Apr; 391(4):395-406. PubMed ID: 29374293
[TBL] [Abstract][Full Text] [Related]
12. Protective Effect of Ipragliflozin on Pancreatic Islet Cells in Obese Type 2 Diabetic db/db Mice.
Takasu T; Takakura S
Biol Pharm Bull; 2018; 41(5):761-769. PubMed ID: 29709913
[TBL] [Abstract][Full Text] [Related]
13. The sodium-glucose cotransporter 2 inhibitor tofogliflozin prevents diabetic kidney disease progression in type 2 diabetic mice.
Li Z; Murakoshi M; Ichikawa S; Koshida T; Adachi E; Suzuki C; Ueda S; Gohda T; Suzuki Y
FEBS Open Bio; 2020 Dec; 10(12):2761-2770. PubMed ID: 33098615
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic Effects of SGLT2 Inhibitor Ipragliflozin and Metformin on NASH in Type 2 Diabetic Mice.
Tahara A; Takasu T
Endocr Res; 2020; 45(2):147-161. PubMed ID: 31955626
[No Abstract] [Full Text] [Related]
15. Impact of sodium glucose linked cotransporter-2 inhibition on renal microvascular oxygen tension in a rodent model of diabetes mellitus.
Hare GMT; Zhang Y; Chin K; Thai K; Jacobs E; Cazorla-Bak MP; Nghiem L; Wilson DF; Vinogradov SA; Connelly KA; Mazer CD; Evans RG; Gilbert RE
Physiol Rep; 2021 Jun; 9(12):e14890. PubMed ID: 34184431
[TBL] [Abstract][Full Text] [Related]
16. Glycemic control by the SGLT2 inhibitor empagliflozin decreases aortic stiffness, renal resistivity index and kidney injury.
Aroor AR; Das NA; Carpenter AJ; Habibi J; Jia G; Ramirez-Perez FI; Martinez-Lemus L; Manrique-Acevedo CM; Hayden MR; Duta C; Nistala R; Mayoux E; Padilla J; Chandrasekar B; DeMarco VG
Cardiovasc Diabetol; 2018 Jul; 17(1):108. PubMed ID: 30060748
[TBL] [Abstract][Full Text] [Related]
17. Effects of the combination of SGLT2 selective inhibitor ipragliflozin and various antidiabetic drugs in type 2 diabetic mice.
Tahara A; Takasu T; Yokono M; Imamura M; Kurosaki E
Arch Pharm Res; 2016 Feb; 39(2):259-270. PubMed ID: 26450351
[TBL] [Abstract][Full Text] [Related]
18. Prevention of progression of diabetic nephropathy by the SGLT2 inhibitor ipragliflozin in uninephrectomized type 2 diabetic mice.
Tahara A; Takasu T
Eur J Pharmacol; 2018 Jul; 830():68-75. PubMed ID: 29702076
[TBL] [Abstract][Full Text] [Related]
19. Ipragliflozin Improves Hepatic Steatosis in Obese Mice and Liver Dysfunction in Type 2 Diabetic Patients Irrespective of Body Weight Reduction.
Komiya C; Tsuchiya K; Shiba K; Miyachi Y; Furuke S; Shimazu N; Yamaguchi S; Kanno K; Ogawa Y
PLoS One; 2016; 11(3):e0151511. PubMed ID: 26977813
[TBL] [Abstract][Full Text] [Related]
20. SGLT2 Inhibitors and the Diabetic Kidney.
Fioretto P; Zambon A; Rossato M; Busetto L; Vettor R
Diabetes Care; 2016 Aug; 39 Suppl 2():S165-71. PubMed ID: 27440829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
